<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/sensei-biotherapeutics-inc-logo-1200x675.jpg/query-dj0yMDIxMDMyOTEyNTUwMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/sensei-biotherapeutics-inc-logo-1200x675.jpg/query-dj0yMDIxMDMyOTEyNTUwMw"/>Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder Millennium Management Llc sold 8,151 shares of the firm's stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $31.01, for a total transaction of $252,762.51. Following the completion of the sale, the insider owned 133,986 shares in the company, valued at $4,154,905.86. This represents a 5.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.</p><p>Millennium Management Llc also recently made the following trade(s): </p><ul><li>On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total transaction of $52,218.84. </li><li>On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total transaction of $13,539.05. </li><li>On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total transaction of $23,629.68. </li><li>On Monday, March 30th, Millennium Management Llc bought 9,533 shares of Sensei Biotherapeutics stock. The shares were acquired at an average price of $25.86 per share, for a total transaction of $246,523.38. </li><li>On Friday, March 27th, Millennium Management Llc bought 15,321 shares of Sensei Biotherapeutics stock. The shares were acquired at an average price of $26.61 per share, for a total transaction of $407,691.81. </li><li>On Thursday, March 26th, Millennium Management Llc bought 5,731 shares of Sensei Biotherapeutics stock. The shares were acquired at an average price of $28.62 per share, for a total transaction of $164,021.22. </li><li>On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total transaction of $40,554.59. </li><li>On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total transaction of $36,397.50. </li><li>On Wednesday, April 1st, Millennium Management Llc bought 6,175 shares of Sensei Biotherapeutics stock. The shares were acquired at an average price of $34.49 per share, for a total transaction of $212,975.75. </li><li>On Tuesday, March 31st, Millennium Management Llc bought 6,005 shares of Sensei Biotherapeutics stock. The shares were acquired at an average price of $28.16 per share, for a total transaction of $169,100.80. </li></ul><h2>Sensei Biotherapeutics Stock Performance</h2><hr/><hr/><p>Shares of Sensei Biotherapeutics stock opened at $20.43 on Friday. The firm's 50-day simple moving average is $28.89 and its 200-day simple moving average is $17.87. Sensei Biotherapeutics, Inc. has a twelve month low of $5.25 and a twelve month high of $36.76. The firm has a market cap of $27.38 million, a P/E ratio of -1.23 and a beta of -0.18. </p><p>Sensei Biotherapeutics (NASDAQ:SNSE - Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($130.83).  On average, equities analysts forecast that  Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current fiscal year. </p><h2>Hedge Funds Weigh In On Sensei Biotherapeutics</h2><p>A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its stake in  Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Free Report) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,516 shares of the company's stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent filing with the Securities and Exchange Commission. 10.50% of the stock is currently owned by institutional investors. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several analysts have recently weighed in on the stock. Zacks Research upgraded shares of Sensei Biotherapeutics to a &#34;hold&#34; rating in a research report on Tuesday, April 21st. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Wall Street Zen lowered shares of Sensei Biotherapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. Finally, Leerink Partners began coverage on shares of Sensei Biotherapeutics in a research report on Monday, April 20th. They issued an &#34;outperform&#34; rating and a $50.00 price target on the stock. One research analyst  has rated the stock with a Buy rating, two have assigned  a Hold rating and one  has issued  a Sell rating to the company. According to MarketBeat, the stock  has an average rating of &#34;Hold&#34; and an average price target of $40.00.</p><p><b>Check Out Our Latest Stock Report on SNSE</b></p><h2>More Sensei Biotherapeutics News</h2><p>Here are the key news stories impacting Sensei Biotherapeutics this week:</p><ul>   <li><span>Positive Sentiment: </span>Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. <i></i><span>Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update</span></li>   <li><span>Neutral Sentiment: </span>The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. <i></i><span>SEC insider filing</span></li>   <li><span>Negative Sentiment: </span>The earnings release showed a very large quarterly loss, with reported EPS of <strong>($131.45)</strong> versus expectations of <strong>($0.62)</strong>, underscoring continued financial volatility and likely limiting enthusiasm for the stock. <i></i><span>Quarterly earnings press release</span></li> </ul><h2>About Sensei Biotherapeutics</h2><p> (Get Free Report)</p><p>Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.  </p><p>The company's lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.</p><h2>See Also</h2><ul><li>Five stocks we like better than Sensei Biotherapeutics</li><li>MarketBeat Week in Review – 05/11 - 05/15</li><li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li><li>Datavalut Gains Traction: 5 Reasons to Sell Now</li><li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05TRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05TRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Sensei Biotherapeutics?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Sensei Biotherapeutics and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260413094022_pushgold-bullion-163553640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260413094022_pushgold-bullion-163553640.jpg"/></p><div><p>Trump's gold order: the announcement they won't put on the front page</p><p>On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...</p><p><span>Reagan Gold Group</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTA5MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTA5MQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260429162234_pushelon-musk-7465608640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260429162234_pushelon-musk-7465608640.jpg"/></p><div><p>Elon's new &#34;super startup&#34;</p><p>Adam O'Dell - the analyst who recommended Palantir before it became the top S&amp;P 500 performer - has identified...</p><p><span>Banyan Hill Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE2MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE2MQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260311160021_pushainewer-1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260311160021_pushainewer-1.jpg"/></p><div><p>CODE RED: AI Meltdown Imminent?</p><p>After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...</p><p><span>Paradigm Press</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE4OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE4OA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260420143007_pushwallstreet.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="201" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260420143007_pushwallstreet.jpg"/></p><div><p>Your book is inside</p><p>The &#34;Sucker's Bet&#34; Most New Options Traders Fall For  Most people who try options lose money the same way. ...</p><p><span>Profits Run</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTAwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTAwNQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png"/></p><div><p>SpaceX eyes a 1.75 trillion valuation - here's what to know</p><p>Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260511203658_pushgoldnew-1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260511203658_pushgoldnew-1.jpg"/></p><div><p>Oil is settling in yuan now - here's what that means for gold</p><p>Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...</p><p><span>Golden Portfolio</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTQxMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTQxMw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://mde-images.marketbeat.com/doc-conversion/2026/04/034166e16ffc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1600" height="899" original-src="https://imageproxy.pbkrs.com/https://mde-images.marketbeat.com/doc-conversion/2026/04/034166e16ffc.png"/></p><div><p>The cat is out the bag</p><p>Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...</p><p><span>Porter &amp; Company</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTMzMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTMzMA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260225085049_pushelonnew-5.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260225085049_pushelonnew-5.jpg"/></p><div><p>Louis Navellier: My #1 AI stock for 2026 (name &amp; ticker inside)</p><p>Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...</p><p><span>InvestorPlace</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODMzMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODMzMw"/></p></div></div></div>                     </div>                 </div></div>

SNSE

<p>Millennium Management LLC, a major shareholder of Sensei Biotherapeutics (NASDAQ:SNSE), sold 8,151 shares at an average price of $31.01, totaling $252,762.51. This sale reduced their ownership by 5.73%, leaving them with 133,986 shares valued at approximately $4.15 million. The transaction was disclosed to the SEC. Recent trades by Millennium include both sales and purchases of Sensei shares, reflecting active management of their investment.</p>

Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Millennium Management Llc Sells 8,151 Shares